White G C, Roberts H R, Kingdon H S, Lundblad R L
Blood. 1977 Feb;49(2):159-70.
Factors affecting the coagulant activity of two different prothrombin complex concentrates have been investigated using a sensitive in vitro assay developed in this laboratory. One concentrate contained substantial amounts of potentially thrombogenic material, while the other, which was deliberately fortified with antithrombin III and heparin during production, was judged to be relatively nonthrombogenic. The coagulant activity of the thrombogenic concentrate has been partially identified and was due largely to the presence of coagulation factos IXa and Xa. Neither concentrate contained detectable thrombin. However, after incubation with calcium or various polyamines, large amounts of additional coagulant material, including thrombin, appeared. Heparin and antithrombin III not only neutralized the thrombogenic materials present in the thrombogenic concentrate, but also inhibited the de novo generation of coagulant enzymes during incubation with calcium. The implication of these studies on the preparation of prothrombin complex concentrates and on host susceptibility to thrombosis during the clinical use of these concentrates is discussed.
利用本实验室开发的一种灵敏的体外检测方法，对影响两种不同凝血酶原复合物浓缩物凝血活性的因素进行了研究。一种浓缩物含有大量潜在的致血栓形成物质，而另一种在生产过程中特意添加了抗凝血酶III和肝素，被认为相对不易形成血栓。已部分鉴定出致血栓形成浓缩物的凝血活性，其主要归因于凝血因子IXa和Xa的存在。两种浓缩物均未检测到凝血酶。然而，在与钙或各种多胺孵育后，出现了大量额外的凝血物质，包括凝血酶。肝素和抗凝血酶III不仅中和了致血栓形成浓缩物中存在的致血栓形成物质，而且还抑制了在与钙孵育期间凝血酶的重新产生。讨论了这些研究对凝血酶原复合物浓缩物制备以及这些浓缩物临床使用期间宿主血栓形成易感性的意义。
